4NE1 Stock Overview Engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Accolade, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Accolade Historical stock prices Current Share Price US$3.20 52 Week High US$12.80 52 Week Low US$2.82 Beta 2.2 1 Month Change 0% 3 Month Change -1.84% 1 Year Change -73.77% 3 Year Change -77.62% 5 Year Change n/a Change since IPO -90.59%
Recent News & Updates
Transcarent, Inc. agreed to acquire Accolade, Inc. (NasdaqGS:ACCD) from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others for approximately $620 million. Jan 10 Accolade to Delist Shares from Nasdaq Transcarent, Inc. agreed to acquire Accolade, Inc. (NasdaqGS:ACCD) from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others for approximately $620 million. Jan 08
Accolade, Inc. to Report Q3, 2025 Results on Jan 09, 2025 Dec 16
Second quarter 2025 earnings released: US$0.30 loss per share (vs US$0.43 loss in 2Q 2024) Oct 08
Accolade, Inc. to Report Q2, 2025 Results on Oct 08, 2024 Sep 18 See more updates
Transcarent, Inc. agreed to acquire Accolade, Inc. (NasdaqGS:ACCD) from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others for approximately $620 million. Jan 10 Accolade to Delist Shares from Nasdaq Transcarent, Inc. agreed to acquire Accolade, Inc. (NasdaqGS:ACCD) from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others for approximately $620 million. Jan 08
Accolade, Inc. to Report Q3, 2025 Results on Jan 09, 2025 Dec 16
Second quarter 2025 earnings released: US$0.30 loss per share (vs US$0.43 loss in 2Q 2024) Oct 08
Accolade, Inc. to Report Q2, 2025 Results on Oct 08, 2024 Sep 18
First quarter 2025 earnings released: US$0.35 loss per share (vs US$0.53 loss in 1Q 2024) Jun 28
Accolade, Inc., Annual General Meeting, Aug 06, 2024 Jun 24
Accolade, Inc. to Report Q1, 2025 Results on Jun 27, 2024 Jun 15
Full year 2024 earnings released: US$1.33 loss per share (vs US$6.45 loss in FY 2023) Apr 26
Accolade, Inc. to Report Q4, 2024 Results on Apr 25, 2024 Apr 04
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President Mar 20
Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 3Q 2023) Jan 09
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ending February 29, 2024 and Year Ending February 28, 2025 Jan 09
Accolade, Inc. to Report Q3, 2024 Results on Jan 08, 2024 Dec 12
Second quarter 2024 earnings released: US$0.43 loss per share (vs US$0.66 loss in 2Q 2023) Oct 06
Accolade, Inc. to Report Q2, 2024 Results on Oct 04, 2023 Sep 21
Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience Sep 19
First quarter 2024 earnings released: US$0.53 loss per share (vs US$4.92 loss in 1Q 2023) Jul 01
Accolade, Inc., Annual General Meeting, Aug 08, 2023 Jun 28
Accolade, Inc. to Report Q1, 2024 Results on Jun 29, 2023 Jun 14
Full year 2023 earnings released: US$6.45 loss per share (vs US$1.93 loss in FY 2022) Apr 30
Accolade, Inc. Announces Changes to Its Board of Directors Feb 17
Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.34 profit in 3Q 2022) Jan 11
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending February 28, 2023; Provides Earnings Guidance for the Year Ending February 29, 2024 Jan 10
Accolade, Inc. to Report Q3, 2023 Results on Jan 09, 2023 Dec 21
Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.97 loss in 2Q 2022) Oct 08
Accolade, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending November 30, 2022 and Fiscal Year Ending February 28, 2023 Oct 07
Accolade, Inc. to Report Q2, 2023 Results on Oct 06, 2022 Sep 20
Chairman of the Board & CEO recently bought €173k worth of stock Aug 04
Accolade, Inc. Appoints Kelli Burns as Senior Vice President, Chief Information Security Officer Jul 26
Accolade, Inc. Provides Earnings Guidance for Second Quarter Ending August 31, 2022 and Fiscal Year Ending February 28, 2023 Jul 01
Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 2000 Growth Index Jun 26
Accolade, Inc., Annual General Meeting, Jul 26, 2022 Jun 25
Accolade, Inc. to Report Q1, 2023 Results on Jun 30, 2022 Jun 22 Accolade, Inc. announced delayed annual 10-K filing
Full year 2022 earnings released: US$1.93 loss per share (vs US$1.73 loss in FY 2021) May 01
Accolade, Inc. to Report Q4, 2022 Results on Apr 28, 2022 Apr 15
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter, Fiscal Year Ending February 28, 2022 and Fiscal Year 2023 Jan 12
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Jan 11
Second quarter 2022 earnings released: US$0.97 loss per share (vs US$0.47 loss in 2Q 2021) Oct 08
Accolade Introduces Personalized Healthcare Category Sep 23
High number of new directors Aug 01
High number of new directors Jul 27
First quarter 2022 earnings released: US$0.84 loss per share (vs US$1.86 loss in 1Q 2021) Jul 10 Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 2500 Value Index
Accolade, Inc. (NasdaqGS:ACCD) completed the acquisition of PlushCare, Inc. Jun 10
Independent Chairman J. Cline has left the company Jun 09
Independent Director William Frist has left the company Jun 09
Full year 2021 earnings released: US$1.73 loss per share (vs US$9.13 loss in FY 2020) May 09
Accolade, Inc. Provides Earnings Guidance for the First Quarter Ending May 31, 2021 and Fiscal Year Ending February 28, 2022 May 07 Shareholder Returns 4NE1 DE Healthcare DE Market 7D 0% -0.7% -0.02% 1Y -73.8% 38.8% 15.1%
See full shareholder returns
Return vs Market: 4NE1 underperformed the German Market which returned 15.3% over the past year.
Price Volatility Is 4NE1's price volatile compared to industry and market? 4NE1 volatility 4NE1 Average Weekly Movement 6.0% Healthcare Industry Average Movement 4.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4NE1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4NE1's weekly volatility (6%) has been stable over the past year.
About the Company Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions.
Show more Accolade, Inc. Fundamentals Summary How do Accolade's earnings and revenue compare to its market cap? 4NE1 fundamental statistics Market cap €540.65m Earnings (TTM ) -€173.66m Revenue (TTM ) €430.28m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4NE1 income statement (TTM ) Revenue US$446.72m Cost of Revenue US$231.64m Gross Profit US$215.08m Other Expenses US$395.38m Earnings -US$180.30m
Last Reported Earnings
Nov 30, 2024
Earnings per share (EPS) -2.21 Gross Margin 48.15% Net Profit Margin -40.36% Debt/Equity Ratio 66.9%
How did 4NE1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 18:07 End of Day Share Price 2025/01/08 00:00 Earnings 2024/11/30 Annual Earnings 2024/02/29
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Accolade, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Gillmor Baird Zhilin Long Berenberg Allen Lutz BofA Global Research
Show 21 more analysts 